METHOD OF TREATING DISSEMINATED RENAL CELL CARCINOMA Russian patent published in 2020 - IPC A61K31/436 A61K39/395 A61P35/00 G01N33/53 G01N33/574 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and aims at treating renal cell carcinoma. Nivolumab is administered intravenously drop-by-drop into the preparation in dose of 3 mg/kg of body once every two weeks. Computed tomography is performed every 8 weeks. If observing X-ray signs of disease progression, the levels of spontaneous production of IL-10 (X1), induced production of IL-8 (X2), spontaneous production of IL-4 (X3), induced production of TNF-α (X4) and absolute concentration of natural killers with T-lymphocyte receptors (CD3+CD16+56+, X5). Discriminant functions F1 and F2 are calculated from obtained values. If F1>F2, pseudo-progression is established in the patient and treatment is continued in the previous mode, and if F2>F1 – treatment is carried out with the preparation Everolimus, which is administered in dose of 10 mg per day orally in form of eight-week cycles until progressing.

EFFECT: invention enables improving survival rates in patients with renal cell carcinoma.

1 cl, 12 tbl, 2 ex